20D Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Cidara Therapeutics Inc

Watchlist Manager

Watchlist

Price: 9.716 EUR

Market Cap: €98.6m

C	Cidara Therapeutics Inc SWB:20D	US
	JD.Com Inc HKEX:89618	CN
	Rio Tinto Ltd F:CRA1	AU
	State Bank of India NSE:SBIN	IN
A	Agilent Technologies Inc SWB:AG8	US
B	BP PLC F:BPE5	UK
N	New York Times Co XMUN:NYT	US
S	Skyworks Solutions Inc DUS:AWM	US
Q	Quinstreet Inc F:5Q8	US
T	Tile Shop Holdings Inc F:2TS	US
B	BE Semiconductor Industries NV SWB:BSI	NL
R	Rigel Pharmaceuticals Inc SWB:RI2A	US
	Spie SA OTC:SPIWF	FR
A	Astron Corp Ltd ASX:ATR	AU

Profitability Summary

Cidara Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Sustainable 3Y Average Gross Margin

30%

Low Operating Margin

Negative 3Y Average Operating Margin

-8 933%

Low Net Margin

Negative 3Y Average Net Margin

-9 358%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-9 809%

Negative ROE

-69%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-379%

Declining ROIC

-92% > -238%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.